A fixed combination of metoprolol and chlorthalidone in hypertension. A clinical trial in general practice.
Seventy-one patients with mild-to-moderate essential hypertension completed 14 weeks' treatment with a single daily dose of fixed combination of metoprolol tartrate 100 mg and chlorthalidone 25 mg (Logroton; Geigy). This represents 6958 patient-days of treatment. Mean blood pressures, both supine and standing, and pulse rates were reduced to and maintained at clinically acceptable levels during the trial period. No patient prematurely discontinued treatment because of insufficient therapeutic effect. Two patients discontinued the medication for drug-related reasons. Patient compliance was excellent and the preparation was well tolerated. The preparation was judged to be therapeutically effective in more than 80% of cases and is a valuable formulation for antihypertensive therapy.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002752:Chlorthalidone / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D005654:Fundus Oculi / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011412:Propanolamines / Q000008:administration & dosage*; D011674:Pulse / Q000187:drug effects
D004338:Drug Combinations; D011412:Propanolamines; D008790:Metoprolol; D002752:Chlorthalidone; D011188:Potassium